Clinical trials
Phase 3 Renal Insufficiency, Chronic trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Active, not recruiting | 8 |
| Recruiting | 8 |
| Terminated | 8 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 7 |
| Amgen | 5 |
| Bayer | 4 |
| GlaxoSmithKline | 4 |
| Novartis Pharmaceuticals | 4 |
| Boehringer Ingelheim | 3 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 |
| Novo Nordisk A/S | 3 |
| Tanabe Pharma Corporation | 3 |
| Akebia Therapeutics | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 59 |
| Kidney Diseases | 9 |
| Kidney Failure, Chronic | 8 |
| Anemia | 6 |
| Diabetes Mellitus, Type 2 | 6 |
| Glomerulonephritis, IGA | 6 |
| Proteinuria | 5 |
| Glomerulonephritis | 4 |
| Hyperparathyroidism, Secondary | 4 |
| Hypertension | 4 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.